Sepsis-Associated Encephalopathy
7
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy
Optic Nerve Sheath Diameter / Eyeball Transverse Diameter Ratio and Prognosis of Sepsis Associated Encephalopathy
Role of MSCT Volumetry in Assessment of Brain Atrophy in Septic Patients
Establishment of a Cohort of Patients With Sepsis-associated Encephalopathy (SAE)
Adjunctive Sedation With Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy
Correlation of Formyl Peptide Receptor 1 With Sepsis-related Encephalopathy
The Dynamic Change of MMN in Patients With Sepsis Associated Encephalopathy